Statera Biopharma, Inc. (STAB)

0.0003 0.0000 (0.00%) At close: 09:30AM EDT

Statera Biopharma, Inc.

4333 Corbett Drive
Suite 1082
Fort Collins, CO 80525
United States
888 613 8802
https://www.staterabiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 46

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Michael Kevin Handley	CEO, Pres & Chairman	2.87M	N/A	1972
Mr. Christopher Zosh	Exec. VP of Fin., Interim Principal Financial Officer & Interim Principal Accounting Officer	N/A	N/A	1976
Dr. Robert W. Buckheit Jr., Ph.D.	Chief Technology Officer	N/A	N/A	1960

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.

Corporate Governance

Statera Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.